Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H17ClN2 |
| Molecular Weight | 236.74 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC1=C(C)NC2=C1C=C(Cl)C=C2
InChI
InChIKey=KSYMELKKLOFABL-UHFFFAOYSA-N
InChI=1S/C13H17ClN2/c1-9-11(6-7-16(2)3)12-8-10(14)4-5-13(12)15-9/h4-5,8,15H,6-7H2,1-3H3
| Molecular Formula | C13H17ClN2 |
| Molecular Weight | 236.74 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
ST1936 is a potent serotonin 6 (5-HT6) receptor agonist with activity in animal pharmacological models for central nervous system disorders: effect of ST 1936 was investigated on depression-like experimental models. In addition, ST 1936 displays moderate affinity for human α2 adrenergic receptors, shown to increase Ca2+ concentration and phosphorylation of Fyn kinase, and regulate the activation of ERK1/2 in cloned cells.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3371 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21549693 |
28.8 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| ST1936 stimulates cAMP, Ca2+, ERK1/2 and Fyn kinase through a full activation of cloned human 5-HT6 receptors. | 2011-07-01 |
|
| A microdialysis study of ST1936, a novel 5-HT6 receptor agonist. | 2011-03 |
|
| 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. | 2005-10-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21185318
in rats: It was investigated the effect of ST1936 (5-10-20 mg/kg/ip) on dialysate DA, NA and 5-HT in the medial prefrontal cortex (PFCX) and in the shell and core of the nucleus accumbens (NAc). Systemic administration of ST1936 dose-dependently increased dialysate DA and NA in the NAc shell and PFCX and to a lesser extent in the NAc core.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21549693
Curator's Comment: ST1936 binds to human 5-HT(6) receptors with good affinity (K(i)=28.8 nM). ST1936 also exhibited some moderate binding affinity for 5HT(2B), 5HT(1A), 5HT(7) receptors and adrenergic α receptors. ST1936 behaved as a full 5-HT(6) agonist on cloned cells and was able to increase Ca(2+) concentration, phosphorylation of Fyn kinase, and regulate the activation of ERK1/2 that is a downstream target of Fyn kinase.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:54:33 GMT 2025
by
admin
on
Wed Apr 02 09:54:33 GMT 2025
|
| Record UNII |
4R5ZNV2CHC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID001045649
Created by
admin on Wed Apr 02 09:54:33 GMT 2025 , Edited by admin on Wed Apr 02 09:54:33 GMT 2025
|
PRIMARY | |||
|
ST-1936
Created by
admin on Wed Apr 02 09:54:33 GMT 2025 , Edited by admin on Wed Apr 02 09:54:33 GMT 2025
|
PRIMARY | |||
|
9921064
Created by
admin on Wed Apr 02 09:54:33 GMT 2025 , Edited by admin on Wed Apr 02 09:54:33 GMT 2025
|
PRIMARY | |||
|
4R5ZNV2CHC
Created by
admin on Wed Apr 02 09:54:33 GMT 2025 , Edited by admin on Wed Apr 02 09:54:33 GMT 2025
|
PRIMARY | |||
|
1210-81-7
Created by
admin on Wed Apr 02 09:54:33 GMT 2025 , Edited by admin on Wed Apr 02 09:54:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST |